Hormonal Status, Performance and Health in Elite Female Athlete

NCT ID: NCT05028959

Last Updated: 2021-08-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-09-15

Study Completion Date

2025-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The repercussions of the hormonal status of high-level sportswomen on their performance and health as well as on the Athlete's Biological Passport (ABP) have been little studied and remain poorly known. The investigators therefore propose to contribute to the improvement of current knowledge by determining, thanks to the implementation of a multidisciplinary monitoring, with the use of various tests and matrices, in female elite athletes and recreational athletes (control group):

* 1\) the impact of cycle phase, absence of cycle or contraceptive use on physical and psychological performance, health as well as on ABP;
* 2\) the potential confounding effects of the athlete's environment
* 3\) correlations between the different matrices analyzed

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Volunteers to be studied: 80 healthy female subjects (16 to 30 years old), divided into 2 groups:

Group 1: 60 athletes, from different sports disciplines, in amenorrhea, with menstrual cycle or taking contraceptives

Group 2: 20 leisure sports subjects with menstrual cycle or taking contraceptives

Following the oral and written information of the project, the subjects have a minimum of 15 days of reflection before signing the written consent form. They will have the possibility, at any time, to voluntarily interrupt the study without having to justify themselves.

Investigations to be performed:

1. Annual complete clinical examination :
2. "Out-of-competition" follow-up, time frame 6 months

* medical, nutritional and respiratory monitoring
* biological monitoring
* psychological monitoring
* performance monitoring
3. Non-invasive "in-competition" monitoring, only for Group 1, once in a year on the day before/after a major competition:

* biological monitoring
* psychological monitoring
* performance monitoring (interview)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

female elite athlete menstrual phase amenorrhea hormonal contraception performance health Athlete Biological Passport

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

2 groups : female athletes and leisure sports women
Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Female athletes

highly trained subjects

Group Type EXPERIMENTAL

Multidisciplinary monitoring of healthy women

Intervention Type OTHER

Multidisciplinary monitoring

Leisure sport women

recreational sportswomen practicing regular physical activity

Group Type EXPERIMENTAL

Multidisciplinary monitoring of healthy women

Intervention Type OTHER

Multidisciplinary monitoring

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Multidisciplinary monitoring of healthy women

Multidisciplinary monitoring

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Group 1: high-level athletes (qualified for national/international championships and/or training at least 15 hours/week)
* Group 2: recreational athletes who practice a regular physical activity

Exclusion Criteria

* Participation in another trial
* History of cardiac pathology
* High blood pressure
* History of ulcers and other gastrointestinal disorders
* Myasthenia
* Renal insufficiency
* Person not affiliated or not benefiting from a social security system
Minimum Eligible Age

16 Years

Maximum Eligible Age

30 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Université Paris-Saclay-Assistance publique des hôpitaux de Paris

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Emmanuelle Duron

Head of Geriatry, Principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Emmanuelle DURON, PU-PH

Role: CONTACT

Phone: 33144083503

Email: [email protected]

Christine Le-Scanff, PU

Role: CONTACT

Phone: 33169156198

Email: [email protected]

References

Explore related publications, articles, or registry entries linked to this study.

Ackerman KE, Singhal V, Baskaran C, Slattery M, Campoverde Reyes KJ, Toth A, Eddy KT, Bouxsein ML, Lee H, Klibanski A, Misra M. Oestrogen replacement improves bone mineral density in oligo-amenorrhoeic athletes: a randomised clinical trial. Br J Sports Med. 2019 Feb;53(4):229-236. doi: 10.1136/bjsports-2018-099723. Epub 2018 Oct 9.

Reference Type BACKGROUND
PMID: 30301734 (View on PubMed)

Crewther BT, Cook CJ. The salivary testosterone response to a chance-determined contest is associated with face-gazing behaviours in athletic women. Horm Behav. 2018 Jul;103:107-110. doi: 10.1016/j.yhbeh.2018.06.011. Epub 2018 Jul 2.

Reference Type BACKGROUND
PMID: 29953884 (View on PubMed)

Casey E, Reese M, Okafor E, Chun D, Gagnon C, Nigl F, Dhaher YY. Influence of Menstrual Cycle and Oral Contraceptive Phase on Spinal Excitability. PM R. 2016 Sep;8(9):860-8. doi: 10.1016/j.pmrj.2016.01.013. Epub 2016 Feb 10.

Reference Type BACKGROUND
PMID: 26872589 (View on PubMed)

Cornelli U, Belcaro G, Cesarone MR, Finco A. Analysis of oxidative stress during the menstrual cycle. Reprod Biol Endocrinol. 2013 Aug 2;11:74. doi: 10.1186/1477-7827-11-74.

Reference Type BACKGROUND
PMID: 23915183 (View on PubMed)

Eklund E, Berglund B, Labrie F, Carlstrom K, Ekstrom L, Hirschberg AL. Serum androgen profile and physical performance in women Olympic athletes. Br J Sports Med. 2017 Sep;51(17):1301-1308. doi: 10.1136/bjsports-2017-097582. Epub 2017 Jun 23.

Reference Type BACKGROUND
PMID: 28646101 (View on PubMed)

Emami F, Kordi Yoosefinejad A, Motealleh A. Comparison of static and dynamic balance during early follicular and ovulation phases in healthy women, using simple, clinical tests: a cross sectional study. Gynecol Endocrinol. 2019 Mar;35(3):257-260. doi: 10.1080/09513590.2018.1519788. Epub 2018 Oct 23.

Reference Type BACKGROUND
PMID: 30350735 (View on PubMed)

Hausmann M, Slabbekoorn D, Van Goozen SH, Cohen-Kettenis PT, Gunturkun O. Sex hormones affect spatial abilities during the menstrual cycle. Behav Neurosci. 2000 Dec;114(6):1245-50. doi: 10.1037//0735-7044.114.6.1245.

Reference Type BACKGROUND
PMID: 11142657 (View on PubMed)

Julian R, Hecksteden A, Fullagar HH, Meyer T. The effects of menstrual cycle phase on physical performance in female soccer players. PLoS One. 2017 Mar 13;12(3):e0173951. doi: 10.1371/journal.pone.0173951. eCollection 2017.

Reference Type BACKGROUND
PMID: 28288203 (View on PubMed)

Kishali NF, Imamoglu O, Katkat D, Atan T, Akyol P. Effects of menstrual cycle on sports performance. Int J Neurosci. 2006 Dec;116(12):1549-63. doi: 10.1080/00207450600675217.

Reference Type BACKGROUND
PMID: 17145688 (View on PubMed)

Kluft C, Leuven JA, Helmerhorst FM, Krans HM. Pro-inflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment. Vascul Pharmacol. 2002 Aug;39(3):149-54. doi: 10.1016/s1537-1891(02)00304-x.

Reference Type BACKGROUND
PMID: 12616983 (View on PubMed)

Langdeau JB, Day A, Turcotte H, Boulet LP. Gender differences in the prevalence of airway hyperresponsiveness and asthma in athletes. Respir Med. 2009 Mar;103(3):401-6. doi: 10.1016/j.rmed.2008.09.023. Epub 2008 Nov 21.

Reference Type BACKGROUND
PMID: 19027280 (View on PubMed)

Lebrun CM, Petit MA, McKenzie DC, Taunton JE, Prior JC. Decreased maximal aerobic capacity with use of a triphasic oral contraceptive in highly active women: a randomised controlled trial. Br J Sports Med. 2003 Aug;37(4):315-20. doi: 10.1136/bjsm.37.4.315.

Reference Type BACKGROUND
PMID: 12893716 (View on PubMed)

Nose-Ogura S, Yoshino O, Dohi M, Kigawa M, Harada M, Hiraike O, Onda T, Osuga Y, Fujii T, Saito S. Risk factors of stress fractures due to the female athlete triad: Differences in teens and twenties. Scand J Med Sci Sports. 2019 Oct;29(10):1501-1510. doi: 10.1111/sms.13464. Epub 2019 Jun 9.

Reference Type BACKGROUND
PMID: 31100189 (View on PubMed)

Otaka M, Chen SM, Zhu Y, Tsai YS, Tseng CY, Fogt DL, Lim BH, Huang CY, Kuo CH. Does ovulation affect performance in tennis players? BMJ Open Sport Exerc Med. 2018 Jan 27;4(1):e000305. doi: 10.1136/bmjsem-2017-000305. eCollection 2018.

Reference Type BACKGROUND
PMID: 29464104 (View on PubMed)

Schaumberg MA, Jenkins DG, Janse DE Jonge XA, Emmerton LM, Skinner TL. Oral Contraceptive Use Dampens Physiological Adaptations to Sprint Interval Training. Med Sci Sports Exerc. 2017 Apr;49(4):717-727. doi: 10.1249/MSS.0000000000001171.

Reference Type BACKGROUND
PMID: 27898641 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FEM-2020

Identifier Type: -

Identifier Source: org_study_id